NCT07850765Completed
Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets
sEMa-LIFE: Unveiling Semaglutide's Impact on Daily Life - Patient and Physicians Experience Across Six Emerging Markets
Source: ClinicalTrials.gov · Last updated 30 Sept 2026
Brief summary (registry, in English)
The purpose of this study is to assess semaglutide's impact on daily life from participants and physicians experience.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1260 (actual)
- First submitted
- 23 Sept 2026
- Start date
- 28 Aug 2026
- Primary completion date
- 31 Aug 2026
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Obesity
- NCT number
- NCT07850765
What you commit to
- Study type: Observational
- Participants enrolled: 1260
- From 28 Aug 2026 to the primary completion date, 31 Aug 2026
- 6 sites in 6 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- This is a secondary database analysis
Who the study is looking for
- Aged 18 years or older
- Currently receiving Wegovy for at least 16 weeks, who at initiation of Wegovy had either: BMI of more than or equal to (≥) 27 to less than (\<) 30 kilogram per meter square (kg/m\^2) with at least one weight-related comorbidity and BMI of ≥30 kg/m\^2
- Not currently involved in a clinical trial for overweight or obesity
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novo Nordisk Investigational Site Coordinator of this site? Confirm its status | Abu Dhabi | United Arab Emirates | Unknown status |
| Novo Nordisk Investigational Site Coordinator of this site? Confirm its status | Jerusalem | Israel | Unknown status |
| Novo Nordisk Investigational Site Coordinator of this site? Confirm its status | Mexico City | Mexico | Unknown status |
| Novo Nordisk Investigational Site Coordinator of this site? Confirm its status | Riyadh | Saudi Arabia | Unknown status |
| Novo Nordisk Investigational Site Coordinator of this site? Confirm its status | Pretoria | South Africa | Unknown status |
| Novo Nordisk Investigational Site Coordinator of this site? Confirm its status | Ankara | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.